Clinical Trial: Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)

Study Status: Available
Recruit Status: Available
Study Type: Expanded Access

Official Title: Temporary Authorization for Use (ATU) to Avelumab for Treatment of Adult Patients With Metastatic Merkel Cell Carcinoma (mMCC)

Brief Summary: Expanded access to Avelumab solution for infusion will be made available for adult patients with mMCC whose disease has progressed after receiving at least one prior chemotherapy.

Detailed Summary:
Sponsor: Merck KGaA

Current Primary Outcome:

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Merck KGaA

Dates:
Date Received: March 20, 2017
Date Started:
Date Completion:
Last Updated: May 8, 2017
Last Verified: March 2017